BGM 0504
Alternative Names: BGM-0504Latest Information Update: 11 Aug 2026
At a glance
- Originator BrightGene Bio-medical technology
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity; Type 2 diabetes mellitus
Most Recent Events
- 04 Aug 2026 Phase-III clinical trials in Type 2 diabetes mellitus (Treatment-naive) in China (SC) (NCT07743983)
- 30 Jun 2026 BrightGene Bio-medical technology plans a phase II trial for Obesity (Treatment-experienced) in China (PO) (NCT07658560)
- 05 May 2026 BrightGene Bio-Medical Technology plans to submit a New Drug Application (NDA) for BGM 0504 for Obesity in China